- Home
- PAVM vs NLSP Comparison
PAVM vs NLSP Comparison
Compare PAVM & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- NLSP
- Stock Information
- Founded
- PAVM 2014
- NLSP 2015
- Country
- PAVM United States
- NLSP Switzerland
- Employees
- PAVM N/A
- NLSP N/A
- Industry
- PAVM Medical/Dental Instruments
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- PAVM Health Care
- NLSP Health Care
- Exchange
- PAVM Nasdaq
- NLSP Nasdaq
- Market Cap
- PAVM 12.0M
- NLSP 12.4M
- IPO Year
- PAVM 2016
- NLSP 2021
- Fundamental
- Price
- PAVM $0.61
- NLSP $2.86
- Analyst Decision
- PAVM Strong Buy
- NLSP
- Analyst Count
- PAVM 1
- NLSP 0
- Target Price
- PAVM $19.00
- NLSP N/A
- AVG Volume (30 Days)
- PAVM 158.5K
- NLSP 385.9K
- Earning Date
- PAVM 08-11-2025
- NLSP 07-07-2025
- Dividend Yield
- PAVM N/A
- NLSP N/A
- EPS Growth
- PAVM N/A
- NLSP N/A
- EPS
- PAVM 0.96
- NLSP N/A
- Revenue
- PAVM $1,993,000.00
- NLSP N/A
- Revenue This Year
- PAVM N/A
- NLSP N/A
- Revenue Next Year
- PAVM $455.63
- NLSP N/A
- P/E Ratio
- PAVM $0.64
- NLSP N/A
- Revenue Growth
- PAVM N/A
- NLSP N/A
- 52 Week Low
- PAVM $0.55
- NLSP $1.30
- 52 Week High
- PAVM $1.90
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- PAVM 43.11
- NLSP 68.80
- Support Level
- PAVM $0.59
- NLSP $2.51
- Resistance Level
- PAVM $0.63
- NLSP $3.08
- Average True Range (ATR)
- PAVM 0.04
- NLSP 0.21
- MACD
- PAVM -0.00
- NLSP 0.04
- Stochastic Oscillator
- PAVM 27.06
- NLSP 75.17
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.